Cargando…
Pre-clinical and Clinical Safety Studies of CMX-2043: A Cytoprotective Lipoic Acid Analogue for Ischaemia–Reperfusion Injury
CMX-2043 is an α-lipoic acid analogue targeted to reduction of cellular injury and organ damage due to ischaemia–reperfusion injury (IRI). It has been shown to be effective in a rat model of cardiac IRI. The studies here reported evaluate its safety and pharmacokinetic profile in preparation for hum...
Autores principales: | Kates, Steven A, Lader, Alan S, Casale, Ralph, Beeuwkes, Reinier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270215/ https://www.ncbi.nlm.nih.gov/pubmed/24751172 http://dx.doi.org/10.1111/bcpt.12254 |
Ejemplares similares
-
PReS-FINAL-2043: Cardiac involvement in juvenile idiopathic arthritis
por: Rossetto, E, et al.
Publicado: (2013) -
PROJECT ADMINISTRATION AGREEMENT KN2043/BE
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2012) -
Development of CMX001 for the Treatment of Poxvirus Infections
por: Lanier, Randall, et al.
Publicado: (2010) -
Gamma spectrometry in the ITWG CMX-4 exercise
por: Lakosi, L., et al.
Publicado: (2018) -
Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model
por: Parker, Scott, et al.
Publicado: (2008)